Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials